ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Mar 10, 2023 15:04 JST
Source:
Eisai
Eisai Receives the "Basic Achievement Grand Prize" at the 2023 J-Win Diversity Award
TOKYO, Mar 10, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it was selected as the winner of the "Basic Achievement Grand Prize" at the "2023 J-Win Diversity Award" held by non-profit organization Japan Women's Innovative Network (NPO J-Win).
The "J-Win Diversity Award" has been held annually since 2008 with the aim of accelerating the promotion of diversity and inclusion (D&I) in Japanese companies by awarding leading businesses that are promoting D&I. Among the Company Prizes, Eisai was selected as the winner of the "Basic Achievement Grand Prize", which is the highest award within the "Basic Category" covering businesses who demonstrate the significance and purpose of female empowerment, developing systems and frameworks with set goals, and are taking action as a first step towards D&I promotion.
Reasons For Award-Winner Selection
Promoting D&I by viewing acquisition of diverse human talents and their successes as essential for realizing their corporate concept. While promoting company-wide initatives with the "DE&I (Diversity, Equity & Inclusion) Promotion Committee", encouraging independent activities appropriate to onsite challenges through "DE&I projects" at each department. Further expansion in the number of female managers is expected down the road.
Highly Regarded Measures/Initiatives
1) Top management commitment and promotional framework for D&I
- Promoting D&I by regarding acquisition and retention of diverse human talents and their successes as essential to evolve the "hhc (human health care)" concept and realize an "hhceco company"
- Promoting activities by division, setting up "DE&I Projects" for global functions, such as corporate, R&D and manufacturing operations as well as each regional function, in parallel with implementing the "DE&I Promotion Committee" throughout the company.
- Plans to introduce a new personnel assessment system from FY 2023, which utilizes a behavioral assessment item "Diversity & Synergy" to further focus on diversity.
2) Developing female leaders
- Implementing E-Win (Eisai Women's Innovative Network) program to encourage personal growth and foster career awareness/aspirations
3) Reforming corporate culture/promoting increased awareness
- Promoting dialogues within the organization by leveraging monthly engagement survey
Eisai's corporate concept (also known as the hhc Concept) is to give first thought to patients and the people in the daily living domain, and increase the benefits that healthcare provides to them as well as meet their diversified healthcare needs worldwide. Eisai aims to realize the spiral of knowledge generated by diversity, regardless of differences in nationality, gender, age, etc., leading to the creation of innovation. Eisai also acquired third party appraisals including "Platinum Kurumin", an accreditation for organizations implementing high level parenting support by Ministry of Health, Labour and Welfare, as well as "the New Diversity Management Selection 100" and "Health & Productivity Management Outstanding Organizations" by Ministry of Economy, Trade and Industry.
Eisai is promoting DE&I throughout the company to ensure it has the diversity to meet increasingly diverse needs of patients and the people in the daily living domain.
For more information about Eisai's DE&I promotion, please visit it's corporate website.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
For more information, visit www.eisai.com/news/2023/news202318.html.
Source: Eisai
Sectors: BioTech
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer
Apr 03, 2026 12:33 JST
Hitachi Rail announces agreement to acquire Clever Devices, marking its growth as a global digital mobility player
Apr 03, 2026 11:09 JST
OMRON Healthcare and UCSF launch AFib trial
Apr 03, 2026 00:00 JST
DENSO and FoodVentures Strengthen Collaboration through Capital Partnership in the Agricultural Sector
Apr 02, 2026 19:56 JST
JRC, SKY Perfect JSAT, and Sharp Collaborate to Promote the Ministry of Defense's Publicly Announced Project "Development and Demonstration of Resiliency Technology for Multi-Orbit Communications Systems" Selected for JRC
Apr 02, 2026 16:01 JST
MHIEC Completes Construction of Nanbu Relay Center for Nagasaki Prefecture's Ken'ou-Kennan Clean Authority
Apr 02, 2026 14:57 JST
Mazda EZ-6/Mazda6e Wins 2026 World Car Design of the Year Award
Apr 02, 2026 11:47 JST
Honda Makes Gachaco a Consolidated Subsidiary by Subscribing to New Shares of Gachaco Issued Through Third-party Allotment
Apr 01, 2026 22:09 JST
DENSO Hosted "DENSO DIALOG DAY 2026", Delivers Mid-Term Management Plan "CORE 2030"
Apr 01, 2026 21:54 JST
MHI President Eisaku Ito Offers Words of Encouragement to New Employees at the Company's 2026 Welcoming Ceremony
Apr 01, 2026 13:35 JST
MHI Completes the Transfer Procedures for its Domestic Onshore Wind Power Business
Apr 01, 2026 13:26 JST
Toyota Motor Corporation aims to join Daimler Truck and Volvo Group as equal shareholder in the fuel cell joint venture cellcentric
Mar 31, 2026 23:39 JST
Honda Announces the Establishment of PathAhead Co., Ltd., a Startup Originated from IGNITION, a Honda New Business Creation Program
Mar 31, 2026 21:58 JST
Hitachi Digital Services Strengthens OT-IT Integration with Manufacturing Operations Management Platform
Mar 31, 2026 19:14 JST
Fujitsu and Osaka University of Health and Sport Sciences partner to innovate sports performance with skeleton recognition AI
Mar 31, 2026 17:42 JST
DOCOMO and SK Telecom Publish White Paper on Requirements for Advancing vRAN and AI-RAN in Mobile Networks
Mar 31, 2026 11:00 JST
NEC Supports Ooredoo Algeria in Modernizing Enterprise Network Security with high-performance next-generation firewalls (NGFW)
Mar 31, 2026 10:50 JST
MOL and Hitachi Launch Initiative to Convert Used Ships into Floating Data Centers
Mar 30, 2026 19:21 JST
Resona Holdings, BrainPad, and Fujitsu sign basic agreement for collaboration to transform financial operations with data and AI and advance next-generation data utilization
Mar 30, 2026 15:55 JST
MHI Innovative Combustion Dynamics Laboratory is Established at Kyoto University with the Aim of Developing and Socially Implementing World-Leading Technology
Mar 30, 2026 12:53 JST
More Latest Release >>
Related Release
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
3/27/2026 8:14:00 PM JST
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
3/27/2026 6:19:00 PM JST
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
3/23/2026 11:19:00 AM JST
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
3/19/2026 10:54:00 AM JST
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
3/17/2026 7:49:00 PM JST
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
3/12/2026 5:21:00 PM JST
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
3/11/2026 12:07:00 PM JST
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
3/2/2026 9:49:00 AM JST
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
2/16/2026 2:03:00 PM JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
2/10/2026 1:34:00 PM JST
More Press release >>